信达生物制药（苏州）有限公司 Innovent BiologicsInc
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Innovent and Roche Enter into A Strategic Collaboration to Discover and Develop Multiple Products including Cellular Therapies and Bispecific Antibodies 2020-06-09 07:30
Innovent Announces the Preliminary Results of the Anti-CTLA-4 Monoclonal Antibody IBI310 in a Phase 1 Clinical Study 2020-06-03 07:30
Innovent Announced the Preliminary Results of the Anti-PD-1/PD-L1 Bispecific Antibody IBI318 in a Phase 1 Clinical Study 2020-06-02 07:30
Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type) 2020-06-01 07:30
Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma 2020-06-01 07:30
Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma 2020-06-01 07:30
Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type) 2020-06-01 07:30
Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma 2020-06-01 07:30
Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma 2020-06-01 07:30
Innovent Biologics Announced the Results of the Phase 1b Clinical Study of TYVYT® (Sintilimab Injection) in Combination with IBI305 (Bevacizumab Biosimilar) in the Treatment of Advanced Hepatocellular Carcinoma 2020-06-01 07:30
Innovent Announces First Patient Dosed in A Phase 1 Clinical Trial of Anti-TIGIT Monoclonal Antibody in China 2020-05-26 07:30
Innovent Biologics and MD Anderson Announce a Strategic Collaboration to Develop anti-PD-1 Therapy TYVYT® (Sintilimab Injection) in Rare Cancers 2020-05-19 07:30
Innovent Announces Key Results from a Number of Clinical Studies to Be Presented at the 2020 American Society of Clinical Oncology (ASCO) Annual Meeting 2020-05-15 07:30
TYVYT® (Sintilimab Injection) ORIENT-2 Study Met its Primary Endpoint of Overall Survival in the Second-Line Treatment of Patients with Advanced or Metastatic Esophageal Squamous Cell Carcinoma 2020-05-14 07:30
Tyvyt® (Sintilimab Injection) Combined with Gemzar® (Gemcitabine for Injection) and Platinum Chemotherapy Met the Predefined Primary Endpoint in the Phase 3 ORIENT-12 Study as First-Line Therapy in Patients with Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer 2020-05-07 07:30
Innovent Announces First Patient Dosed in a Pivotal Trial of Parsaclisib in Patients with Indolent Lymphoma in China 2020-04-28 07:50
Innovent and Eli Lilly Announce NMPA Acceptance of a Supplemental New Drug Application for Sintilimab in Combination with ALIMTA® (Pemetrexed) and Platinum as First-Line Therapy in Non-squamous NSCLC 2020-04-24 07:50
Innovent Biologics Announces FDA Approval of Pemazyre™ (Pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma 2020-04-20 08:00
Innovent Biologics Announces FDA Approval of Pemazyre™ (Pemigatinib) as First Targeted Treatment for Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma 2020-04-20 08:00
Innovent Announces Financial Results for Full Year Ended December 31, 2019 and Corporate Progress 2020-03-31 00:08
1 15 16 17 18 19 20